Today, the Executive VP and CFO of Palatin Technologies (PTN), Stephen Wills, bought shares of PTN for $15.35K.
This is Wills’ first transaction since reporting a Buy transaction on DSCI back in August 2015 In addition to Stephen Wills, 2 other PTN executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
PTN’s market cap is $163M and the company has a P/E ratio of 20.86. Currently, Palatin Technologies has an average volume of 3.94M.
Starting in November 2017, PTN received 9 Buy ratings in a row.
Stephen Wills’ trades have generated a 30.4% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Palatin Technologies, Inc. is a biopharmaceutical company which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
